Yellow Fever Monoclonal Antibody Prevents Vaccine-Induced Viremia in Phase 1 Trial

摘要

Investigators used YF17D live virus vaccine as a challenge virus to assess the efficacy of monoclonal antibody in abrogating vaccine-induced viremia. Yellow fever virus (YFV) outbreaks have expanded in South America and Africa and threaten urban areas infested with YFV-competent mosquitoes. No licensed YFV therapeutics are available. Investigators conducted a manufacturer-supported phase 1 clinical trial of a human IgG1 mononclonal antibody (TY014) developed in Chinese hamster ovary cells. TY014 targets an epitope on the YFV envelope protein. Investigators assessed its efficacy in preventing viremia, which occurs in >80% of recipients of the live YFV vaccine (YF17D). TY014 was administered as intravenous infusion.